Protagonist Therapeutics (PTGX) Presents at Digestive Disease Week (DDW) 2022

| --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | A Phase 2 randomized, double-blind, placebocontrolled, multi-center study to evaluate the | | | | | safety and efficacy of the oral, gut-restricted ɑ4β 7 integrin peptide antagonist PN-943 in ...